News | April 28, 2024
Evonik expands capacity for customized Resomer powder biomaterials
New solvent-free micronization technology expanded at the Darmstadt site in Germany
New solvent-free micronization technology expanded at the Darmstadt site in Germany
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Sales reflect continued strong growth in oncology and vaccines
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Subscribe To Our Newsletter & Stay Updated
